PT - JOURNAL ARTICLE AU - SO-WOON KIM AU - SUNG-IM DO AU - KIYONG NA TI - External Validation of <em>ALK</em> and <em>ROS1</em> Fusions Detected Using an Oncomine Comprehensive Assay AID - 10.21873/anticanres.15274 DP - 2021 Sep 01 TA - Anticancer Research PG - 4609--4617 VI - 41 IP - 9 4099 - http://ar.iiarjournals.org/content/41/9/4609.short 4100 - http://ar.iiarjournals.org/content/41/9/4609.full SO - Anticancer Res2021 Sep 01; 41 AB - Background/Aim: This study aimed to assess the yield of an Oncomine comprehensive assay v3 (OCAv3)-based next-generation sequencing (NGS) analysis for detecting anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) fusions in non-small cell lung cancer (NSCLC). Patients and Methods: NGS data from 85 NSCLC cases were reviewed. ALK and ROS1 fusion status was compared to conventional tests. Results: ALK or ROS1 fusion reads were detected in 17 NSCLC cases. Results in 10 NSCLC cases showed concordance with conventional tests, high-count fusion reads, a lack of mutually exclusive mutations of ALK or ROS1, and frequent signet-ring cell component. Seven NSCLC cases showing discordant results exhibited low to intermediate fusion read counts and mutations mutually exclusive from ALK or ROS1. Conclusion: Cases showing high-count fusion reads in OCAv3-based NGS have a strong possibility of carrying ALK or ROS1 fusion. Cases with low- to intermediate-count fusion reads should be interpreted with caution and may require additional confirmative tests.